Takeda buys US biotech PvP Biologics for $330 millionTakeda has bought US biotech PvP Biologics for $330 million, adding a potential new form of therapy for Share XTakeda buys US biotech PvP Biologics for $330 millionhttps://pharmaphorum.com/news/takeda-buys-us-biotech-pvp-biologics-for-330-million/
Takeda buys coeliac drug licence from COUR PharmaceuticalsTakeda has bought a licence for a coeliac disease drug from COUR Pharmaceuticals, after the US biotech announced Share XTakeda buys coeliac drug licence from COUR Pharmaceuticalshttps://pharmaphorum.com/news/takeda-buys-coeliac-drug-licence-from-cour-pharmaceuticals/
GSK buys Avalon-partnered Sitari and its coeliac drugGlaxoSmithKline’s longstanding collaboration with Avalon Ventures has resulted in a first deal – a buyout of Sitari Pharma Share XGSK buys Avalon-partnered Sitari and its coeliac drughttps://pharmaphorum.com/news/gsk-buys-avalon-partnered-sitari-and-its-coeliac-drug/
ImmusanT abandons coeliac disease vaccine after phase 2 flopUS biotech ImmusanT has been left without any R&D programmes in the clinic after pulling a coeliac disease Share XImmusanT abandons coeliac disease vaccine after phase 2 flophttps://pharmaphorum.com/news/immusant-abandons-coeliac-disease-vaccine-after-phase-2-flop/
